Hypothesis: Gemcitabine and carboplatin are safe in tumor-bearing cats.
Animals: Twenty cats with spontaneously occurring carcinomas.
Methods: A cohort of 6 cats received gemcitabine (2 mg/kg IV) on days 1, 8, and 15 and carboplatin (10 mg/kg IV) immediately after gemcitabine on day 1 of a 21-day cycle. A 2nd cohort of 14 cats received carboplatin 4 hours after gemcitabine on day 1 and gemcitabine on day 8 but not day 15. The cycles were repeated every 21 days.
Results: Cats in the 1st cohort received a median of 3.75 cycles per animal (range, 1–6). Two cats (33.3%) developed grade 3 or 4 neutropenia, 1 (16.7%) grade 4 thrombocytopenia, and 1 (16.7%) grade 3 gastrointestinal toxicity. Gemcitabine dose reductions and treatment delays occurred in 1 and 4 cats, respectively. Cats in the 2nd cohort received a median of 2 cycles per animal (range, 0.5–10). Two cats (14.3%) had grade 3 or 4 neutropenia and 1 (7.1%) had grade 3 and 4 gastrointestinal toxicity. One cat required gemcitabine dose reduction and 6 had treatment delays. In the 2nd cohort, of 11 cats with measurable tumors, there was 1 complete response (pancreatic carcinoma) and 1 partial response (squamous cell carcinoma, receiving concurrent nonsteroidal anti-inflammatory drugs).
Conclusions and Clinical Importance: Gemcitabine-carboplatin combination appears moderately well tolerated in tumor-bearing cats. Minimal patient benefit suggests that alternative schedules or combinations of gemcitabine with other agents should be explored. 相似文献
Polybrominated diphenyl ethers (PBDEs) are a class of global flame retardants whose residues have markedly increased in fish and human tissues during the last decade. They belong to persistent and toxic contaminants which need more attention and toxicological study as their degradation in the environment is not well understood. This study characterizes 2,2′,4,4′-tetrabromodiphenyl ether (BDE-47) bioconcentration, elimination and biotransformation in juvenile turbot Psetta maxima, in order to evaluate the risk of its bioaccumulation in the marine environment. During this study, juvenile turbot were exposed to environmentally relevant BDE-47 concentrations from 0.001 to 1 μg/L for 16 days via aqueous exposure. This study found that juvenile turbot bioconcentrated and biotransformed BDE-47. There was no difference in standard length or weight between control and exposed fish. Uptake and elimination of BDE-47 by the turbot during exposure were examined in controlled laboratory experiments. Bioconcentration of BDE-47 was similar in fish from all treatment groups. Bioconcentration was rapid and increased with exposure time, since the bioconcentration factor (BCF) was higher. However, elimination was slower in comparison and low elimination was detected after 10 days in clean water. BDE-47 concentration in water influences the BCF. Half-life ranged between 37 and 108 days and theoretical times t 90 could range from 120 to 358 days. The present study demonstrates a stepwise debromination of BDE-47 to BDE-28.
相似文献Hypothesis: GEM and CARBO are safe for the treatment of dogs with carcinomas.
Animals: Thirty-seven dogs with histologically or cytologically confirmed carcinomas.
Methods: Prospective clinical trial. Dogs were treated with GEM (2 mg/kg, 20–30-minute infusion IV) on Days 1 and 8 and 4 hours later, CARBO (10 mg/kg IV) on Day 1. The cycle was repeated on Day 22.
Results: Thirty-seven dogs (29 with measurable tumor) received a median of 2 cycles (range 0.5–6) for a total of 101 cycles administered. Twelve dogs (32%) developed neutropenia (3 Grade 3, and 5 Grade 4) and 9 (24%) thrombocytopenia (2 Grade 3, and 1 Grade 4). Dogs >20 kg were twice as likely to develop thrombocytopenia ( P = .023). Twenty-seven dogs (73%) had evidence of gastrointestinal (GI) toxicosis, but most signs were of mild to moderate severity and self-limiting. One dog died of treatment-related complications. Overall tumor response rate was 13%. One dog with metastatic prostatic carcinoma achieved a complete remission and 1 dog with intestinal adenocarcinoma and 1 with tonsillar squamous cell carcinoma achieved partial remission. Twelve dogs achieved stable disease for a median of 72 days.
Conclusion and Clinical Importance: GEM and CARBO combination causes mild to moderate hematologic and GI toxicosis in dogs with carcinoma. Response rate in this study was modest, and optimization of dosing of this combination is required. 相似文献